Aldoro Resources Limited

ARN

Aldoro Resources Ltd. engaged in the exploration and development of minerals. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2018-09-13. The firm has a collection of nickel/copper/PGM focused exploration projects and advanced rubidium exploration projects all located in Western Australia. Its projects include Narndee Igneous Complex, Cathedrals Belt Project, Windimurra Igneous Complex, Leinster Project and Niobe Project. The Narndee Igneous Complex is a layered mafic-ultramafic complex covering approximately 700 square kilometers (km2). The Cathedrals Belt Project targets Ni-Cu-Co mineralization in similar settings to the neighboring Mt Alexander Project. Tenement applications E58/518 and E58/519 cover approximately 420 km2 of the Windimurra Igneous Complex. The Leinster Project is located along strike from nickel deposits, such as BHP Billiton’s Leinster Nickel Project and Talisman Mining’s Sinclair Project. The Niobe tantalum-lithium project lies 70 kilometers north-west of Mount Magnet in the Murchison province of Western Australia.

Aura Energy Limited

AEE

Aura Energy Ltd. engages in the exploration and evaluation of uranium, vanadium, gold and base metals. The firm is engaged in exploration and evaluation of uranium, vanadium and gold and base metals in Mauritania and Sweden. The firm is focused on uranium production commencing at the Tiris Project, a greenfield uranium discovery in Mauritania. The company holds 125 square kilometers of virgin Greenstone belt and is located approximately 36 kilometers south of the Kinross 20 Moz Tasiast Mine. Its Haggan deposit is located in Berg municipality in the province of Jamtland in central Sweden. The Haggan Project is a poly-metallic deposit containing economically significant levels of vanadium, sulphate of potash, nickel, zinc, and molybdenum. The company holds a 100% direct interest in the deposit. Its subsidiaries include Vanadis Battery Metals AB, Aura Energy Mauritania Pty Ltd, Tiris Ressources SA, Tiris International Mining Company sarl and others.

Ausmon Resources Limited

AOA

Ausmon Resources Ltd. is an exploration company, which focuses on gold, silver, copper and other base metals. The company is headquartered in Sydney, New South Wales. The company went IPO on 2009-03-31. The firm is engaged in exploration of minerals tenements with a focus on gold, silver, copper, cobalt, nickel, zinc, rare earth elements and other base metals. The Company’s New South Wales exploration licenses include EL 8745 (Kanbarra), EL 8747 (Stirling Vale), EL 9220 (Enmore), EL 9224 (Eureka), EL 9230 (Mt Darling), EL8954 (Brungle Creek) and EL 9252 (McAlpine). Its South Australia exploration license includes EL 6795 (Parrakie), EL 6796 (Mt Rough), EL 6797 (Kingston) and EL 6807 (Wolseley). Its Western Australia exploration licenses include EL 38/3718 (Barneys) and EL 38/3719 (Neckersgat). Its New South Wales exploration licenses covers an area of approximately 791 square kilometers (km2). Its South Australia exploration license covers an area of approximately 3,549 km2 in the Limestone Coast Region south-east of Adelaide within the Loxton Sands or equivalent of the Murray and Otway Basins.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Leederville, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.